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Abstract
Rationale:Despite the acknowledged importance of environmental risk factors in the etiology of narcolepsy, there is little research
on this topic. HIV as a trigger for narcolepsy has not been systematically investigated.
Patient concerns:We describe a case of narcolepsy type 1 (NT1) in an adolescent with HIV infection presenting with increased
daytime sleepiness and excessive weight gain.
Diagnoses: NT1 was diagnosed according to the criteria of the third edition of the International Classiﬁcation of Sleep Disorders
(ICSD-3).
Interventions: Pharmacological treatment with methylphenidate.
Outcomes: Four months after initiation of methylphenidate therapy the increased daytime sleepiness improved and excessive
weight gain stopped.
Lessons:Diagnosis of NT1 can be challenging at disease onset and is often delayed, especially in the pediatric population, because
symptoms usually evolve gradually. The case presented here raises the possibility that the HIV infection may play a role in the
pathogenesis of NT1 serving as trigger for autoimmune-mediated destruction of hypocretin-secreting neurons.
Abbreviations: 3TC = lamivudine, ABC = abacavir, ART = antiretroviral therapy, ATV/r = ritonavir boosted atazanavir, AZT =
zidovudine, BMI = body mass index, CSF = cerebrospinal ﬂuid, ESS = Epworth sleepiness scale, ICSD-3 = third edition of the
International Classiﬁcation of Sleep Disorders, MRI = magnetic resonance imaging, MSLT = multiple sleep latency test, NT1 =
narcolepsy type 1, NVP = nevirapine, PSG = polysomnography, SOREMs = sleep onset REM sleep periods.
Keywords: autoimmunity, HIV, narcolepsy
1. Introduction
Narcolepsy type 1 (NT1) is a chronic neurologic disorder
characterized by excessive daytime sleepiness and cataplexy that
affects approximately 0.047% of the European population.[1]
NT1 is caused by the destruction of over 90% of hypocretin-
secreting neurons leading to a deﬁciency of the neuropeptide
hypocretin (also known as orexin) with low or undetectable levels
in the cerebrospinal ﬂuid (CSF).[2] Epidemiological data reveal a
clear association between narcolepsy and various infections.[3,4]
The pathogenic mechanism underlying this observation is thought
to be an autoimmune-mediated loss of hypocretin-secreting
neurons[5] triggered by certain infections, such as inﬂuenza and
streptococcal infections, or vaccinations, such as the AS03-
adjuvanted inﬂuenza vaccine (Pandemrix, GSK United Kingdom),
yellow fever and tick-born encephalitis virus vaccines.[2,6]
However, the association of HIV infection and narcolepsy has
not been described so far and to the best of our knowledge, there
have been no reports describing an association between the 2
conditions.Wepresent the caseof anadolescentwithHIV infection
under effective antiretroviral treatment who presented with
increased daytime sleepiness combined with excessive weight gain
and eventually was diagnosed with narcolepsy.
2. Case report
The 15-year-old patient was diagnosed with HIV infection at the
age of 8 years in Kinshasa, Democratic Republic of Congo. The
reasons leading to the HIV testing are not known but at that time
his baseline CD4+ T-lymphocyte count was 228cells/mL and no
opportunistic infections were described. His parents had died
under unknown circumstances and a vertically acquired HIV
infection was assumed. Antiretroviral therapy (ART) with
zidovudine, lamivudine and nevirapine (AZT/3TC/NVP) was
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initiated in Kinshasa. At the age of 9 years he was adopted by a
Swiss family and we have been following him in our pediatric
infectious diseases outpatient clinic since then. He showed an
uncomplicated course of the HIV infection with good compliance
and full viral suppression under ART. At the age of 14 years ART
was switched for simpliﬁcation to a once daily regime with
abacavir, lamivudine and ritonavir boosted atazanavir (ABC/
3TC/ATV/r). He well tolerated the new regime and his viral load
remained fully suppressed.
At the age of 15 years, 7 years after theHIV diagnosis, the patient
presentedwithexcessivedaytimesleepiness.Symptomswerenapping
in the afternoon, falling asleep during car journeys, as well as when
playing with the mobile phone, and earlier bedtimes in the evening
with consequent increaseof total sleep time.Nohallucinationswhile
fallingasleeporcataplexyepisodeswere reportedby thepatientorby
family members. However a subtle persistent hypotonic facial
expressionwithoutaclear linktoemotional stimuliwasnoted,which
could be interpreted as cataplectic face.[7] At the same time excessive
weight gain accompanied by increased caloric intake with a
pathological rise in body mass index (BMI) from 23.1 to 27.4kg/
m2withina year corresponding to aweight gainof 15.8kgwithin12
months was observed (Fig. 1).
The clinical examination was unremarkable except for obesity.
Additional investigations revealed no signs of anemia, thyroid
gland dysfunction, or Cushing syndrome. Screening for illicit
drug intake was negative. HIV replication in the CSF was not
present and a cerebral magnetic resonance imaging (MRI) was
normal with no signs of HIV encephalopathy. The Epworth
sleepiness scale (ESS) was pathologic with 15 points (normal 0 to
10) indicating a moderate excessive daytime sleepiness. Given
these ﬁndings narcolepsy and sleep apnea were the most likely
differential diagnosis and a polysomnography (PSG) andmultiple
sleep latency test (MSLT) were conducted. The tests showed
increased sleep onset REM sleep periods (SOREMs) (3 of 4) and a
reduced sleep latency (mean 4minutes and 22 seconds) and were
therefore highly suggestive for narcolepsy. Additionally the
patient tested positive for HLADQB1∗06:02, and the ﬁnding of a
pathologically low hypocretin CSF level (orexin A<20pg/mL)
conﬁrmed the diagnosis of NT1. Given the conﬁrmed diagnosis
of narcolepsy a pharmaceutical treatment was started. Taking
into account potential interactions with the current ART
methylphenidate was chosen over modaﬁnil. Four months after
initiation of methylphenidate therapy the increased daytime
sleepiness improved and excessive weight gain stopped.
3. Discussion
NT1 is one of the main differential diagnoses in patients with
hypersomnia but so far was not described in children with HIV
infection. Diagnosis can be challenging at disease onset and is
often delayed, especially in the pediatric population, because
symptoms usually evolve gradually.[8] Beyond the classical
symptoms (excessive daytime sleepiness, cataplexy, hallucina-
tions, sleep paralysis and nocturnal fragmented sleep), metabolic,
endocrinologic, psychiatric, and psychosocial symptoms can be
present. Excessive weight gain as observed in our patient is a
common symptom in children with narcolepsy.[2] The review by
Merdad et al[9] on sleepiness in adolescents can be a useful
resource for planning complementary investigations. Diagnosis
of NT1 according to the criteria of the third edition of the
International Classiﬁcation of Sleep Disorders (ICSD-3) requires
both of the following:[10]
 The patient has daily periods of irrepressible need to sleep or
daytime lapses into sleep occurring for at least 3 months.
 The presence of cataplexy and amean sleep latency of8minutes
and ≥2 SOREMs on a MSLT or CSF hypocretin deﬁciency.
In addition to PSG, MSLT, and CSF hypocretin levels, HLA
testing is usually performed.[10] The diagnosis of narcolepsy is
important, as symptomatic treatment is available.
The case presented here raises the possibility that the HIV
infection in combinationwith a distinct genetic susceptibility such as
the HLA DQB1∗06:02 haplotype may play a role in the
pathogenesis of NT1 serving as trigger for autoimmune-mediated
destruction of hypocretin-secreting neurons.[4] Other potential
infectious triggers could not be identiﬁed in this case and our
patient was not immunized with 2009 H1N1 inﬂuenza vaccine
(Pandemrix,GSKUnitedKingdom).Anextensive literature research
did not reveal any reports about the association between HIV and
narcolepsy. This might either be because there is no association and
the combination of the 2 conditions was observed by chance in our
patient or because narcolepsy is underdiagnosed in children and
adolescentsdue to its less typical presentation in this population.[7] In
Europe the prevalence of narcolepsy is estimated to be 47 per
100,000 persons[1] and the HIV prevalence in Switzerland is
currently at 250 per 100,000 persons. Therefore the probability to
observe a patient with both conditions combined is expected to be
0.000118% meaning that 9 persons would be living with the
combined condition in Switzerland. Given this fact it is surprising
that no cases havebeen reported so far, but the questionwhether this
is due to underreporting or lack of a causal link, remains open.
Figure 1. The patient’s weight-for-age curve based on the WHO Growth
Charts illustrates the sequence of presenting symptoms: start of excessive
daytime sleepiness (continuous line arrow) followed by crossing upwards of
major weight-for-age percentile lines and stagnation of this trend after the
introduction of symptomatic treatment with metylphenidate (dashed line
arrow).
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Future analysis of large HIV cohorts with a focus on vertically
acquired infection can help to answer the question whether the
prevalence of narcolepsy in HIV infected children and adolescent
is higher compared to the general population.
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